Impact of treating chronic hepatitis C with direct acting antivirals on health-related quality of life: a real-life Egyptian experience
Background Chronic hepatitis C virus (HCV) infection negatively impacts health-related quality of life (HRQL). We aimed to assess patient-reported outcomes (PROs) to evaluate the impact of treating chronic HCV with directly acting antivirals (DAAs) on HRQL. Methods PROs were assessed prospectively using the PROQOL-HCV questionnaire before (week 0), at the end (week 12), and after DAA treatment at week 24. HRQL was measured in six different dimensions: physical health, emotional health, future uncertainty, intimate relationships, social health, and cognitive functions. Results A total of 500 HCV patients receiving DAAs were enrolled; of them, 399 were included in the analysis (median age 57 years, 59% females). HRQL increased significantly between baseline, end of treatment, and week 24 for all dimensions (P < 0.001), more often for physical health in females compared to males (OR = 1.69, 95% CI = 1.1–2.5), for future uncertainty among people with diabetes (1.75, 95% CI = 1.05–2.9), and for cognitive functions among obese patients (OR = 1.98; 95% CI = 1.1–3.3). Improvement in HRQL was less common for intimate relations among females (OR = 0.47; 95% CI = 0.3–0.7) and in patients with cirrhosis (OR = 0.35, 95% CI = 0.1–0.7). Improvement in HRQL was consistently higher in < 60 years compared to ≥ 60 years patients, with a significant difference in social health (P < 0.001) and future uncertainty (P < 0.049) HRQL domains. Conclusion HRQL improved with DAA therapy, a relation consistent across all HRQL dimensions up to 12 weeks after the end of treatment..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Egyptian liver journal - 14(2024), 1 vom: 27. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Elbadry, Mohamed [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Direct acting antivirals (DAAs) |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s43066-024-00317-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054940257 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054940257 | ||
| 003 | DE-627 | ||
| 005 | 20240228064702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240228s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s43066-024-00317-8 |2 doi | |
| 035 | |a (DE-627)SPR054940257 | ||
| 035 | |a (SPR)s43066-024-00317-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Elbadry, Mohamed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of treating chronic hepatitis C with direct acting antivirals on health-related quality of life: a real-life Egyptian experience |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Background Chronic hepatitis C virus (HCV) infection negatively impacts health-related quality of life (HRQL). We aimed to assess patient-reported outcomes (PROs) to evaluate the impact of treating chronic HCV with directly acting antivirals (DAAs) on HRQL. Methods PROs were assessed prospectively using the PROQOL-HCV questionnaire before (week 0), at the end (week 12), and after DAA treatment at week 24. HRQL was measured in six different dimensions: physical health, emotional health, future uncertainty, intimate relationships, social health, and cognitive functions. Results A total of 500 HCV patients receiving DAAs were enrolled; of them, 399 were included in the analysis (median age 57 years, 59% females). HRQL increased significantly between baseline, end of treatment, and week 24 for all dimensions (P < 0.001), more often for physical health in females compared to males (OR = 1.69, 95% CI = 1.1–2.5), for future uncertainty among people with diabetes (1.75, 95% CI = 1.05–2.9), and for cognitive functions among obese patients (OR = 1.98; 95% CI = 1.1–3.3). Improvement in HRQL was less common for intimate relations among females (OR = 0.47; 95% CI = 0.3–0.7) and in patients with cirrhosis (OR = 0.35, 95% CI = 0.1–0.7). Improvement in HRQL was consistently higher in < 60 years compared to ≥ 60 years patients, with a significant difference in social health (P < 0.001) and future uncertainty (P < 0.049) HRQL domains. Conclusion HRQL improved with DAA therapy, a relation consistent across all HRQL dimensions up to 12 weeks after the end of treatment. | ||
| 650 | 4 | |a Direct acting antivirals (DAAs) |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Health-related quality of life (HRQL) |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Patient-reported outcomes (PROs) |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hepatitis C virus (HCV) |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Egypt |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Badawi, Mahmoud |4 aut | |
| 700 | 1 | |a Youssef, Naglaa |4 aut | |
| 700 | 1 | |a Duracinsky, Martin |4 aut | |
| 700 | 1 | |a Saleh, Shereen A. |4 aut | |
| 700 | 1 | |a Funk, Anna |4 aut | |
| 700 | 1 | |a Elessawy, Hagar |4 aut | |
| 700 | 1 | |a Rumpler, Eva |4 aut | |
| 700 | 1 | |a Sayed, Khadiga |4 aut | |
| 700 | 1 | |a Vasiliu, Anca |4 aut | |
| 700 | 1 | |a Madec, Yoann |4 aut | |
| 700 | 1 | |a Fontanet, Arnaud |4 aut | |
| 700 | 1 | |a El-Kassas, Mohamed |0 (orcid)0000-0002-3396-6894 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Egyptian liver journal |d [London] : SpringerOpen, 2011 |g 14(2024), 1 vom: 27. Feb. |w (DE-627)SPR038890755 |w (DE-600)3038187-3 |x 2090-6226 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:1 |g day:27 |g month:02 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s43066-024-00317-8 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 1 |b 27 |c 02 | ||